Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Short-term Investments (2016 - 2025)

Ultragenyx Pharmaceutical has reported Short-term Investments over the past 11 years, most recently at $259.0 million for Q4 2025.

  • Quarterly Short-term Investments fell 40.6% to $259.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $259.0 million through Dec 2025, down 40.6% year-over-year, with the annual reading at $259.0 million for FY2025, 40.6% down from the prior year.
  • Short-term Investments was $259.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $222.7 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $614.8 million in Q4 2022 and troughed at $222.7 million in Q3 2025.
  • The 5-year median for Short-term Investments is $434.3 million (2021), against an average of $421.2 million.
  • Year-over-year, Short-term Investments surged 59.31% in 2021 and then crashed 52.71% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $432.6 million in 2021, then surged by 42.12% to $614.8 million in 2022, then plummeted by 40.86% to $363.6 million in 2023, then increased by 19.9% to $436.0 million in 2024, then tumbled by 40.6% to $259.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Short-term Investments are $259.0 million (Q4 2025), $222.7 million (Q3 2025), and $311.3 million (Q2 2025).